Dave Crichton

[Dave Crichton @on45012]

@ownyourcrohns @MondayNightIBD @SanofiUS I declined participating in Dr Sanjay Murthy’s IBD-dysplasia study bc was concerned with being randomized to the random biopsy arm and didn’t want unnecessary biopsies. I felt an obligation to help and participate as believed it was a worthwhile study.

[Dave Crichton @on45012]

@casanova_lab @thoburn_robert I was wondering the same: when were samples taken, at birth? How are they sure that they precede disease onset and not a result of a yet to be identified infectious trigger that is playing an immune response tug of war? (I don’t have access to the paper).

[Dave Crichton @on45012]

@Bealoquebea @AshkanRA @jalpa_devi @MaiaKayalMD @ShomronH @rafeeq_rm @GorelikYuri @Y_ECCO_IBD @z_bakhshiii Absolutely agree. Maybe new computing will take all the bias out eventually. For sure some patients aren’t always forthcoming about everything; maybe especially so if they’re worried about being kicked out of a potentially helpful treatment arm

[Dave Crichton @on45012]

@Bealoquebea @AshkanRA @jalpa_devi @MaiaKayalMD @ShomronH @rafeeq_rm @GorelikYuri @Y_ECCO_IBD @z_bakhshiii Drugs maybe but more thinking along the lines of diet, exercise, maybe they do an FMT at home etc. Similarly what lifestyle factors negatively impact without being picked up. I suppose the question is more what N is sufficient to make up for any of those easy to overlook factors

[Dave Crichton @on45012]

@Bealoquebea @AshkanRA @jalpa_devi @MaiaKayalMD @ShomronH @rafeeq_rm @GorelikYuri @Y_ECCO_IBD @z_bakhshiii What, if any, self or otherwise guided adjunct therapies may be impacting results that randomization may not be able to nullify?

[Dave Crichton @on45012]

@ABsteward What about adjunctive anti-tnf?

DOI 10.1086/592695

[Dave Crichton @on45012]

@Bealoquebea That’s a lot of trials!

[Dave Crichton @on45012]

@HolubarStefan @Johncalvincoffe EME benefit vs LME sounds like you’ve cut out all or more of the potentially infected tissue. If the pathology is driven by dysbiosis and commensals would there be this significant difference in outcomes between both techniques?

[Dave Crichton @on45012]

@Johncalvincoffe @ign76 @NEJM @NatRevGastroHep @LancetGastroHep @HolubarStefan @IBD_FloMD @ASCRS_1 @ColorectalDis @AmerGastroAssn Did they perform microscopy on these resected tissues?

[Dave Crichton @on45012]

@DrAshokGastro These can’t be from just commensals. Wheres the Ghon lesion?

[Dave Crichton @on45012]

@charlie_lees @guthealthmd What about adding cytokine panels to monitoring?

[Dave Crichton @on45012]

@GutMD_ @MondayNightIBD @DCharabaty @abbvie @JNJInnovMed @TakedaPharma @RedHillBio abx

[Dave Crichton @on45012]

@MikhailaFuller What’s the washout protocol?

[Dave Crichton @on45012]

@MondayNightIBD Monogenic Congenital Infectious Bowel Disease?

[Dave Crichton @on45012]

@rafeeq_rm On its face, preventing nearly half of cases sounds like there might be some statistical voodoo going on?

[Dave Crichton @on45012]

@IBDinsights Not quite treat to target I guess. But predictive nonetheless..

[Mount Sinai Division of Gastroenterology @MountSinaiGI]

DAY 1 of #DDW2026! Marla Dubinsky, MD presents on the importance of early, effective combination therapy at diagnosis of IBD for achieving optimal health outcomes. Special shoutout to @ryanungaro, MD’s research on proteomics to support her talk. Stay tuned for more!

[Dave Crichton @on45012]

@IBDinsights The use of cytokines panels to improve treat to target was also a seemingly positive advancement

[Dave Crichton @on45012]

@NarulaNeeraj @CIRC_CCRM @IBDinsights a good example of positive translation